Avalon Pharmaceuticals

Avalon Pharmaceuticals
Gaithersburg, Md.
Founded: 1999

Why It's Fierce: The company's multi-parameter disease model promises to reduce development time for small molecule drug by two to four years. The key to Avalon's promise is its unique mix of high-throughput screening technology and respected cadre of biologists. Co-founder and CEO Kenneth Carter led Human Genome Sciences' gene mapping program from 1993 to 1998. We think Carter's team is building a powerful portfolio of cancer drugs to complement its drug screening technology platform.

What to look for in 2003: Avalon will emerge this year as one of few survivors in the crowded high throughput screening field.

Avalon Pharmaceuticals

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i